- Difficulty filling vacant positions for highly qualified applicants due to the company's location in a structurally weak region.
- Limited possibilities for using recycled materials due to strict pharmaceutical industry requirements.
- Supply difficulties for some raw materials.
Hevert-Arzneimittel GmbH & Co. KG
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Hevert-Arzneimittel GmbH & Co. KG disclosed greenhouse gas emissions of 4.9K t CO2e (2022); 2262.27 t CO2e reduction from 2021. By scope: Scope 1: 4.1K t CO2e (2022); Scope 2: 3.57 t CO2e (2022). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
4.9K t CO2e (2022); 2262.27 t CO2e reduction from 2021
2023
Renewable Energy
100% green power
of total energy
Water Usage
6.089 Ml (2023)
2023
Waste
88.45 tons (2023)
2023
Energy Use
9.5K GJ (2023)
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 4.1K t CO2e (2022) |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 3.57 t CO2e (2022) |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced carbon emissions by 31% year-on-year in the last climate impact report (2022 compared to 2021).
- Became a climate-neutral company by way of carbon offsetting in 2022.
- Reduced electricity consumption by 5% in 2023 compared to 2022.
- Saved 162 GJ of electricity in 2023 due to LED lighting.
🌱 ESG Focus Areas
EmployeesPartnershipQualityNature